ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PRM Proteome Sciences Plc

3.30
0.00 (0.00%)
Last Updated: 08:00:08
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.30 3.00 3.78 13,314 08:00:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 7.78M 1.33M 0.0045 7.33 9.74M

Proteome Sciences PLC Director/PDMR Shareholding (3668W)

31/07/2018 4:09pm

UK Regulatory


Proteome Sciences (LSE:PRM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Proteome Sciences Charts.

TIDMPRM

RNS Number : 3668W

Proteome Sciences PLC

31 July 2018

31 July 2018

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 27 July 2018, it purchased 525,000 ordinary shares and 118,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.49p and 3.5p respectively per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 56,031,431 equivalent to 18.98% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 56,031,431 Ordinary Shares of the Company representing 18.98% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name:                                      Martin Diggle 
     -----------------------------------------  -------------------------------------- 
      Reason for the notification 
     --------------------------------------------------------------------------------- 
 a)   Position/status:                           Non-Executive Director 
     -----------------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment:            Initial Notification 
     -----------------------------------------  -------------------------------------- 
      Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------------------- 
 a)   Name:                                      Proteome Sciences Plc 
     -----------------------------------------  -------------------------------------- 
 b)   LEI:                                       213800Q62ICXANKU2986 
     -----------------------------------------  -------------------------------------- 
      Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------------------------- 
 a)   Description of the financial instrument,   Ordinary Shares of 1p nominal 
       type of instrument:                        value 
       Identification code:                       GB0003104196 
     -----------------------------------------  -------------------------------------- 
 b)   Nature of the transaction:                 Purchase of Ordinary Shares 
     -----------------------------------------  -------------------------------------- 
 c)   Price(s) and volume(s):                      Price(s)   Volume(s) 
                                                    3.49       525,000 
                                                              ---------- 
                                                    3.5        118,000 
                                                              ---------- 
     -----------------------------------------  -------------------------------------- 
 d)   Aggregated information:                    Single transaction as in 
        *    Aggregated volume:                   4 c) above Average Price   Volume(s) 
                                                   3.492           643,000 
                                                                  ---------- 
        *    Price: 
     -----------------------------------------  -------------------------------------- 
 e)   Date of the transaction:                   27 July 2018 
     -----------------------------------------  -------------------------------------- 
 f)   Place of the transaction:                  London Stock Exchange, 
                                                  AIM (XLON) 
     -----------------------------------------  -------------------------------------- 
 

For further information:

 
 Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive        Tel: +44 (0)20 7043 2116 
  Officer 
 Dr Ian Pike, Chief Scientific Officer 
  Richard Dennis, Chief Commercial 
  Officer 
 
 finnCap Limited (Nominated Adviser & Broker) 
 Geoff Nash/Hannah Boros (Corporate      Tel: +44 (0)20 7220 0500 
  Finance) 
  Abigail Wayne (Broking) 
 

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) ) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator(TM) ). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHSDWFIFFASESW

(END) Dow Jones Newswires

July 31, 2018 11:09 ET (15:09 GMT)

1 Year Proteome Sciences Chart

1 Year Proteome Sciences Chart

1 Month Proteome Sciences Chart

1 Month Proteome Sciences Chart

Your Recent History

Delayed Upgrade Clock